Conference Reports for NATAP

Conference on Retroviruses and Opportunistic Infections (CROI) February 13-16, 2017, Seattle WA Back

CURE at CROI 2017       Impressions of CROI 2017 - written by- Pablo Tebas, MD University of Pennsylvania - (03/01/17)   IAS Cure Report: CROI 2017: Basic Science Review Mario Stevenson, PhD   CROI: Identification of Latency Reversing Agents (LRAs) Active in Diverse Primary T-cell Models of HIV Latency - (02/18/17)   CROI: A Bi-Specific Approach for Targeting IMRs in HIV-1 Latency - (03/02/17)   CROI: 288 Day Drug-Free Remission From HIV Rebound by Allogeneic PBSCT - (02/16/17)   CROI: INTEGRASE AND PROTEASE INHIBITOR CONCENTRATIONS IN LYMPH NODE AND GUT MUCOSAL TISSUE - (03/29/17)   CROI: TLR9 AGONIST TRIGGERS POTENT INTESTINAL ANTIVIRAL RESPONSE IN HIV+ INDIVIDUALS ON ART - (02/23/17)   CROI: TLR7 Agonist GS-9620 (Vesatolimod) Increases Immune-Mediated Clearance of HIV-Infected Cells   CROI: TLR7 Agonist GS-986 Markedly Activates T & B Cells From ART-suppressed Donors - (02/23/17)   CROI: TLR7 Agonist Treatment of SIV+ Monkeys on ART Can Lead to Complete Viral Remission - (02/23/17)   CROI: DEVELOPMENT OF A PKC AGONIST DERIVED FROM INGENOL FOR HIV LATENCY DISRUPTION IN VIVO - - (04/12/17)   Two plenaries in HIV Cure - CROI: The Emerging Potential for HIV Cure for Infants, Children, and Adults - and - ADVANCES IN CELLULAR THERAPY IN CANCER AND HIV - (02/22/17)   CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses - (03/16/17)